The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Open accessAbstract
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa isolates are frequent causes of serious nosocomial infections that may compromise the selection of antimicrobial therapy. The goal of this review is to summarize recent epidemiologic, microbiologic, and clinical data pertinent to the therapeutic management of patients with infections caused by MDR/XDR-P. aeruginosa. Historically, conventional antipseudomonal β-lactam antibiotics have been used for the empiric treatment of MDR/XDR-P. aeruginosa. Owing to the remarkable capacity of P. aeruginosa to confer resistance via multiple mechanisms, these traditional therapies are often rendered ineffective. To increase the likelihood of administering empiric antipseudomonal therapy with in vitro activity, a second agent from a different antibiotic class is often administered concomitantly with a traditional antipseudomonal β-lactam. However, combination therapy may pose an increased risk of antibiotic toxicity and secondary infection, notably, Clostridioides difficile. Multiple novel agents that demonstrate in vitro activity against MDR-P. aeruginosa (e.g., β-lactam/β-lactamase inhibitor combinations and cefiderocol) have been recently granted US Food and Drug Administration (FDA) approval and are promising additions to the antipseudomonal armamentarium. Even so, comparative clinical data pertaining to these novel agents is sparse, and concerns surrounding the scarcity of antibiotics active against refractory MDR/XDR-P. aeruginosa necessitates continued assessment of alternative therapies. This is particularly important in patients with cystic fibrosis (CF) who may be chronically colonized and suffer from recurrent infections and disease exacerbations due in part to limited efficacious antipseudomonal agents. Bacteriophages represent a promising candidate for combatting recurrent and refractory infections with their ability to target specific host bacteria and circumvent traditional mechanisms of antibiotic resistance seen in MDR/XDR-P. aeruginosa. Future goals for the management of these infections include increased comparator clinical data of novel agents to determine in what scenario certain agents may be preferred over others. Until then, appropriate treatment of these infections requires a thorough evaluation of patient- and infection-specific factors to guide empiric and definitive therapeutic decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449 · cited 2×
“aeruginosa, with the main update including an expanded set of categories from the 2008 CDC definition that included monobactams (aztreonam), phosphonic acids (fosfomycin), and polymyxins [6].”
BackgroundTacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367 · cited 1×
“OXA-10 exhibits ESBL activity and confers ceftazidime and aztreonam resistance, while OXA31 confers resistance to cefepime [40].”
BackgroundAntibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Bacterial Quorum Sensing: Its Role in Virulence and Possibilities for Its Control
Rutherford, S. T., & Bassler, B. L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a012427 · Cited by 2,129
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Lung Infections Associated with Cystic Fibrosis
Lyczak, J. B., Cannon, C. L., & Pier, G. B. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.194-222.2002 · Cited by 1,628
Aminoglycoside modifying enzymes
Ramirez, M. S., & Tolmasky, M. E. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.08.003 · Cited by 1,464
Pseudomonas aeruginosa: all roads lead to resistance
Breidenstein, E. B. M., de la Fuente-Núñez, C., & Hancock, R. E. W. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.04.005 · Cited by 1,286
Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance
Fernández, L., & Hancock, R. E. W. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00043-12 · Cited by 892
Jault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y.-A., Resch, G., Rousseau, A. F., Ravat, F., Carsin, H., Le Floch, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30482-1 · Cited by 874
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
How to manage Pseudomonas aeruginosa infections
Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018) · Drugs in Context · doi:10.7573/dic.212527 · Cited by 746
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
Chan, B. K., Sistrom, M., Wertz, J. E., Kortright, K. E., Narayan, D., & Turner, P. E. (2016) · Scientific Reports · doi:10.1038/srep26717 · Cited by 715
Bacterial Persister Cell Formation and Dormancy
Wood, T. K., Knabel, S. J., & Kwan, B. W. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.02636-13 · Cited by 703
Phage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Mulcahy, L. R., Burns, J. L., Lory, S., & Lewis, K. (2010) · Journal of Bacteriology · doi:10.1128/jb.01651-09 · Cited by 631
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
Döring, G., Conway, S. P., Heijerman, H. G. M., Hodson, M. E., Høiby, N., Smyth, A., Touw, D. J., & the Consensus Committee, F. (2000) · European Respiratory Journal · doi:10.1034/j.1399-3003.2000.16d30.x · Cited by 620
Kadri, S. S., Adjemian, J., Lai, Y. L., Spaulding, A. B., Ricotta, E., Prevots, D. R., Palmore, T. N., Rhee, C., Klompas, M., Dekker, J. P., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy378 · Cited by 605
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205073109 · Cited by 545
Antimicrobial resistance of Pseudomonas aeruginosa biofilms
Drenkard, E. (2003) · Microbes and Infection · doi:10.1016/j.micinf.2003.08.009 · Cited by 520
Population and evolutionary dynamics of phage therapy
Levin, B. R., & Bull, J. J. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro822 · Cited by 511
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1478 · Cited by 441
Structure, function and regulation of Pseudomonas aeruginosa porins
Chevalier, S., Bouffartigues, E., Bodilis, J., Maillot, O., Lesouhaitier, O., Feuilloley, M. G. J., Orange, N., Dufour, A., & Cornelis, P. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux020 · Cited by 423
Motsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 422
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab295 · Cited by 390
Wagenlehner, F. M., Umeh, O., Steenbergen, J., Yuan, G., & Darouiche, R. O. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62220-0 · Cited by 388
Zhanel, G. G., Lawrence, C. K., Adam, H., Schweizer, F., Zelenitsky, S., Zhanel, M., Lagacé-Wiens, P. R. S., Walkty, A., Denisuik, A., Golden, A., et al. (2018) · Drugs · doi:10.1007/s40265-017-0851-9 · Cited by 377
Kollef, M. H., Nováček, M., Kivistik, Ü., Réa-Neto, Á., Shime, N., Martin-Loeches, I., Timsit, J.-F., Wunderink, R. G., Bruno, C. J., Huntington, J. A., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30403-7 · Cited by 345
Aslam, S., Lampley, E., Wooten, D., Karris, M., Benson, C., Strathdee, S., & Schooley, R. T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa389 · Cited by 342
Zhanel, G. G., Chung, P., Adam, H., Zelenitsky, S., Denisuik, A., Schweizer, F., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Walkty, A., et al. (2014) · Drugs · doi:10.1007/s40265-013-0168-2 · Cited by 340
Taylor, P. K., Yeung, A. T. Y., & Hancock, R. E. W. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.09.003 · Cited by 340
Lodise, T. P., Patel, N., Kwa, A., Graves, J., Furuno, J. P., Graffunder, E., Lomaestro, B., & McGregor, J. C. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00338-07 · Cited by 318
Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence
Davies, J. C. (2002) · Paediatric Respiratory Reviews · doi:10.1016/s1526-0550(02)00003-3 · Cited by 300
Boucher, J. C., Yu, H., Mudd, M. H., & Deretic, V (1997) · Infection and Immunity · doi:10.1128/iai.65.9.3838-3846.1997 · Cited by 282
Haidar, G., Philips, N. J., Shields, R. K., Snyder, D., Cheng, S., Potoski, B. A., Doi, Y., Hao, B., Press, E. G., Cooper, V. S., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix182 · Cited by 277
Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa
Hong, D. J., Bae, I. K., Jang, I.-H., Jeong, S. H., Kang, H.-K., & Lee, K. (2015) · Infection & Chemotherapy · doi:10.3947/ic.2015.47.2.81 · Cited by 271
Raman, G., Avendano, E. E., Chan, J., Merchant, S., & Puzniak, L. (2018) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-018-0370-9 · Cited by 269
Berrazeg, M., Jeannot, K., Ntsogo Enguéné, V. Y., Broutin, I., Loeffert, S., Fournier, D., & Plésiat, P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00825-15 · Cited by 268
Li, H., Luo, Y.-F., Williams, B. J., Blackwell, T. S., & Xie, C.-M. (2012) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2011.10.001 · Cited by 266
Law, N., Logan, C., Yung, G., Furr, C.-L. L., Lehman, S. M., Morales, S., Rosas, F., Gaidamaka, A., Bilinsky, I., Grint, P., et al. (2019) · Infection · doi:10.1007/s15010-019-01319-0 · Cited by 260
Pier, G. B., Coleman, F., Grout, M., Franklin, M., & Ohman, D. E. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1895-1901.2001 · Cited by 258
Markoishvili, K., Tsitlanadze, G., Katsarava, R., Glenn, J., Morris Jr., M. D., & Sulakvelidze, A. (2002) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2002.01451.x · Cited by 243
Hackel, M. A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J. A., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01968-17 · Cited by 235
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
Di Pasquale, M. F., Sotgiu, G., Gramegna, A., Radovanovic, D., Terraneo, S., Reyes, L. F., Rupp, J., González del Castillo, J., Blasi, F., Aliberti, S., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy723 · Cited by 234
Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals
Payne, R. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109520 · Cited by 216
Fraile-Ribot, P. A., Cabot, G., Mulet, X., Periañez, L., Martín-Pena, M. L., Juan, C., Pérez, J. L., & Oliver, A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx424 · Cited by 207
Pogue, J. M., Kaye, K. S., Veve, M. P., Patel, T. S., Gerlach, A. T., Davis, S. L., Puzniak, L. A., File, T. M., Olson, S., Dhar, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz816 · Cited by 206
Yamano, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz827 · Cited by 191
Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa
Dreier, J., & Ruggerone, P. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00660 · Cited by 189
Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
Lapuebla, A., Abdallah, M., Olafisoye, O., Cortes, C., Urban, C., Landman, D., & Quale, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00830-15 · Cited by 181
Henrichfreise, B., Wiegand, I., Pfister, W., & Wiedemann, B. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00148-07 · Cited by 179
Challenges in severe community-acquired pneumonia: a point-of-view review
Torres, A., Chalmers, J. D., Dela Cruz, C. S., Dominedò, C., Kollef, M., Martin-Loeches, I., Niederman, M., & Wunderink, R. G. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05519-y · Cited by 177
Mikhail, S., Singh, N. B., Kebriaei, R., Rice, S. A., Stamper, K. C., Castanheira, M., & Rybak, M. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00779-19 · Cited by 171
Self-citationSaiman, L., Mehar, F., Niu, W. W., Neu, H. C., Shaw, K. J., Miller, G., & Prince, A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.532 · Cited by 164
Bassetti, M., Castaldo, N., Cattelan, A., Mussini, C., Righi, E., Tascini, C., Menichetti, F., Mastroianni, C. M., Tumbarello, M., Grossi, P., et al. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.001 · Cited by 162
Adaptive resistance to antibiotics in bacteria: a systems biology perspective
Sandoval‐Motta, S., & Aldana, M. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1335 · Cited by 159
Stachyra, T., Péchereau, M.-C., Bruneau, J., Claudon, M., Frère, J., Miossec, C., Coleman, K., & Black, M. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00568-10 · Cited by 145
Winkler, M., Papp‐Wallace, K. M., Hujer, A. M., Domitrovic, T., Hujer, K. M., Hurless, K. N., Tuohy, M. J., Hall, G. S., & Bonomo, R. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04238-14 · Cited by 143
Bacteriophage Therapy of Chronic Nonhealing Wound: Clinical Study
Gupta, P., Singh, H. S., Shukla, V. K., Nath, G., & Bhartiya, S. K. (2019) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734619835115 · Cited by 141
Livermore, D. M., Mushtaq, S., Meunier, D., Hopkins, K. L., Hill, R., Adkin, R., Chaudhry, A., Pike, R., Staves, P., & Woodford, N. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx136 · Cited by 139
Mukherjee, S., Moustafa, D. A., Stergioula, V., Smith, C. D., Goldberg, J. B., & Bassler, B. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814023115 · Cited by 139
Jorgensen, S. C. J., Trinh, T. D., Zasowski, E. J., Lagnf, A. M., Bhatia, S., Melvin, S. M., Steed, M. E., Simon, S. P., Estrada, S. J., Morrisette, T., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz522 · Cited by 135
Self-citationYoung, K., Painter, R. E., Raghoobar, S. L., Hairston, N. N., Racine, F., Wisniewski, D., Balibar, C. J., Villafania, A., Zhang, R., Sahm, D. F., et al. (2019) · BMC Microbiology · doi:10.1186/s12866-019-1522-7 · Cited by 132
Sader, H. S., Castanheira, M., Duncan, L. R., & Flamm, R. K. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.04.012 · Cited by 131
Lahiri, S. D., Walkup, G. K., Whiteaker, J. D., Palmer, T., McCormack, K., Tanudra, M. A., Nash, T. J., Thresher, J., Johnstone, M. R., Hajec, L., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv004 · Cited by 129
Chang, R. Y. K., Das, T., Manos, J., Kutter, E. M., Morales, S., & Chan, H. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0315-0 · Cited by 129
Gallagher, J. C., Satlin, M. J., Elabor, A., Saraiya, N., McCreary, E. K., Molnar, E., El‐Beyrouty, C., Jones, B. M., Dixit, D., Heil, E. L., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy280 · Cited by 127
Recio, R., Mancheño‐Losa, M., Viedma, E., Villa, J., Orellana, M. Á., Lora‐Tamayo, J., & Cháves, F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01759-19 · Cited by 126
Alcalde‐Rico, M., Olivares‐Pacheco, J., Alvarez‐Ortega, C., Cámara, M., & Martínez, J. L. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02752 · Cited by 115
Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria
Tam, V. H., Chang, K., Zhou, J. M., Ledesma, K. R., Phe, K., Gao, S., Françoise Van Bambeke, A., Díaz, A. M. S., Zamorano, L., Oliver, A., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx001 · Cited by 108
Mensa, J., Barberán, J., Soriano, À., Llinares, P., Marco, F., Cantón, R., Bou, G., del Castillo, J. M. G., Maseda, E., Azanza, et al. (2018) · Europe PMC (PubMed Central) · Cited by 101
Gill, C. M., Aktaþ, E., Alfouzan, W. A., Bourassa, L. A., Brink, A. J., Burnham, C. D., Cantón, R., Carmeli, Y., Falcone, M., Kiffer, C. R. V., et al. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04308-0 · Cited by 99
Fraile-Ribot, P. A., Zamorano, L., Orellana, R., del Barrio-Tofiño, E., Sánchez-Diener, I., Cortés-Lara, S., López-Causapé, C., Cabot, G., Bou, G., Martı́nez-Martı́nez, L., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02165-19 · Cited by 87
Stone, G. G., Newell, P., Gasink, L. B., Broadhurst, H., Wardman, A., Yates, K., Chen, Z., Song, J., & Chow, J. W. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky204 · Cited by 85
Tabak, Y. P., Merchant, S., Ye, G., Vankeepuram, L., Gupta, V., Kurtz, S., & Puzniak, L. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.06.005 · Cited by 83
Streling, A. P., Al‐Obaidi, M. M., Lainhart, W., Zangeneh, T. T., Khan, A., Dinh, A. Q., Hanson, B., Arias, C. A., & Miller, W. R. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1909 · Cited by 78
Cañestro, M. D., Periañez, L., Mulet, X., Martín-Pena, M. L., Fraile-Ribot, P. A., Ayestarán, I., Colomar, A., Núñez, B., Macia, M. D., Novo, A., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3361-0 · Cited by 76
Lodise, T. P., Miller, C., Graves, J. P., Furuno, J. P., McGregor, J. C., Lomaestro, B. M., Graffunder, E. M., & McNutt, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00851-06 · Cited by 69
Montero, M., Sala, M., Riu, M., Belvis, F. X., Salvadó, M., Grau, S., Horcajada, J. P., Álvarez-Lerma, F., Terradas, R., Orozco‐Levi, M., et al. (2009) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0850-1 · Cited by 66
Rubio, A. M., Kline, E. G., Jones, C. E., Chen, L., Kreiswirth, B. N., Nguyen, M. H., Clancy, C. J., Cooper, V. S., Haidar, G., Tyne, D. V., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00084-21 · Cited by 66
OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China
Fang, Z.-L., Zhang, L., Huang, Y.-M., et al. (2013) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2013.10.027 · Cited by 61
Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
Escolà‐Vergé, L., Pigrau, C., Arcos, I. L., Arévalo, Á., Viñado, B., Campany, D., Larrosa, N., Nuvials, X., Ferrer, R., Len, Ó., et al. (2018) · Infection · doi:10.1007/s15010-018-1133-5 · Cited by 60
Jorgensen, S. C. J., Trinh, T. D., Zasowski, E. J., Lagnf, A. M., Simon, S. P., Bhatia, S., Melvin, S. M., Steed, M. E., Finch, N. A., Morrisette, T., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02291-19 · Cited by 60
Self-citationLob, S. H., Karlowsky, J. A., Young, K., Motyl, M. R., Hawser, S., Kothari, N., & Sahm, D. F. (2020) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001142 · Cited by 60
Dupont, P., Hocquet, D., Jeannot, K., Chavanet, P., & Plésiat, P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki030 · Cited by 53
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.10.028 · Cited by 52
Iregui, A., Khan, Z., Landman, D., & Quale, J. M. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2019.0298 · Cited by 52
Micek, S. T., Reichley, R. M., & Kollef, M. H. (2011) · Medicine · doi:10.1097/md.0b013e318239cf0a · Cited by 47
Lee, M., Abbey, T. C., Biagi, M. J., & Wenzler, E. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115227 · Cited by 46
Pseudomonas aeruginosa: Multi-Drug-Resistance Development and Treatment Options
Meletis, G., & Bagkeri, M. (2013) · InTech eBooks · doi:10.5772/55616 · Cited by 41
Vena, A., Giacobbe, D. R., Mussini, C., Cattelan, A. M., Bassetti, M., Ceftabuse Study Group, Bassetti, M., Vena, A., Castaldo, N., Pecori, D., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa003 · Cited by 40
Rodríguez-Núñez, O., Periañez-Párraga, L., Oliver, A., Munita, J. M., Bote, A. C., Gasch, O., Nuvials, X., Dinh, A., Shaw, R. H., Lomas, J. M., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz416 · Cited by 37
Balandín, B., Ballesteros, D., de Luna, R. R., López-Vergara, L., Pintado, V., Sancho-González, M., Soriano, C., Sánchez-Belmonte, M. J. P.-P., Asensio-Martín, M. J., Fernández, I., et al. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106270 · Cited by 36
Poirel, L., de la Rosa, J. M. O., Kieffer, N., Dubois, V., Jayol, A., & Nordmann, P. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01809-18 · Cited by 34
Real-world use of ceftolozane/tazobactam: a systematic literature review
Puzniak, L., Dillon, R. J., Palmer, T., Collings, H., & Enstone, A. (2021) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-021-00933-8 · Cited by 33
696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
Ito, A., Nishikawa, T., Ishii, R., Kuroiwa, M., Ishioka, Y., Kurihara, N., Sakikawa, I., Ota, T., Rokushima, M., Tsuji, M., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy210.703 · Cited by 29
Sader, H. S., Carvalhaes, C. G., Streit, J. M., Doyle, T. B., & Castanheira, M. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0217 · Cited by 29
Sader, H. S., Duncan, L. R., Doyle, T. B., & Castanheira, M. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab126 · Cited by 28
Hirsch, E. B., Giancola, S. E., Mahoney, M. V. G., & Bias, T. E. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s83844 · Cited by 24
Vinluan, C. M., Hidalgo, J., & Antony, N. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s110946 · Cited by 23
Nolan, P. J., Jain, R., Cohen, L., Finklea, J. D., & Smith, T. T. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115204 · Cited by 14
Cited by
Naik, G. A. R. R., Roy, A. A., Mutalik, S., & Dhas, N. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134977 · Cited by 47
Nair, V. G., Unnikrishnan, V. K., Muralidharan, N., Venkatathri, B. N. S., Lowrence, R. C., YBRD, R., Narbhavi, D., A, A., N, P., & Nagarajan, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-17404-4 · Cited by 8
Metadata
- Authors
- Kunz Coyne, A. J., El Ghali, A., Holger, D., Rebold, N., & Rybak, M. J.
- Venue
- Infectious Diseases and Therapy
- Published
- 2022-02-12
- Volume
- 11
- Issue
- 2
- Pages
- 661-682
- ISSN
- 2193-6382 (ISSN-L)
- 2193-8229
- OpenAlex
- W4211066906
- Cited by
- 275
- References
- 107
- FWCI
- 16.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.